J&J declares Actelion tender offer a success, sees closing in second quarter
ZURICH (Reuters) - Johnson & Johnson declared its $30 billion tender offer for Swiss biotechnology company Actelion successful on Friday, reporting it controlled 77.2 percent of the voting rights after the main offer period.
No comments:
Post a Comment